ImmunoGen Message Board - Msg: 32217118

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	6/28/2019 4:02:31 PM
	Read Replies (1) of 5665

Clearly IMGN's success with IMGN853 will be delayed until a new Phase 3 can be completed. The company is cutting way back on staff to afford it. It seems like the Street like the move, but it's impossible to say how high it may go on that. I'm still of the belief that a ROW partnership for IMGN853 could come at any time, and while IMGN might not go after earlier approval in Europe, I'm not sure that a BP partner wouldn't. The data for the high platinum resistant group certainly is worthy of approval, but clearly the numbers are less than the FDA wants to see, I'm not sure the European authorities aren't more flexible. There will be more information at upcoming medical conferences on each of the products that's advancing and while they dropped one product, it was because the other IGN is far more toxic to the cancer, and appears to be working well, no need to test the less toxic product when the more powerful product is working in patients with no unacceptable side effects. I believe that ESMO is the first conference, and the one where the Phase 3 will be discussed. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next